Agios Pharmaceuticals Stock News

CAMBRIDGE, Mass., June 17, 2020 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) – Analysts at SVB Leerink reduced their Q3 2020 EPS estimates for shares of Agios Pharmaceuticals in a research note issued to investors on Monday, June 15th.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) – Stock analysts at Oppenheimer boosted their Q3 2020 earnings estimates for shares of Agios Pharmaceuticals in a report released on Sunday, June 14th. Oppenh

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target hoisted by analysts at Citigroup from $64.00 to $75.00 in a note issued to investors on Monday, The Fly reports. The firm presently has a “bu

The initial public offering was for a pharmaceutical company that doesn't want to make or sell any drugs.

GlaxoSmithKline got its first taste of synthetically lethal cancer therapies via an acquisition. Now it’s trying for a bigger bite of this emerging drug

Technically speaking, the U.S. benchmarks’ bullish bigger-picture backdrop has thus far weathered a mid-June market whipsaw, writes Michael Ashbaugh.

Viela Bio receives FDA approval for Uplizna. Exelixis starts late stage lung cancer study. Agios reports positive proof of concept study.

Shares in Agios Pharma ticked upwards after the FDA awarded breakthrough status to a companion diagnostic to vorasidenib,

Agios Pharmaceuticals (NASDAQ:AGIO)‘s stock had its “hold” rating reiterated by equities researchers at Oppenheimer in a research note issued to investors on Monday, AnalystRatings.com reports.

Treasurer of the State of North Carolina raised its stake in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 71.0% during the first quarter, according to its most recent 13F filing with the Secur

Shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) reached a new 52-week high during mid-day trading on Friday after Piper Sandler raised their price target on the stock from $70.00 to $80.00. Piper Sa

Agios reports good results from trial of blood disorder drug

Crispr Therapeutics and Vertex Pharmaceuticals stocks initially popped Friday after the biotech companies unveiled updated results for a gene-editing drug in blood-disease treatment.

Scientists say this model could be a workaround in face of longstanding legal and ethical restrictions on researching embryos. Other science news focuses on trials for inherited blood disorders, si…